{{Drugbox
| verifiedrevid = 450106371
| IUPAC_name = ''N''-[(2''E'')-5-amino-5-methylhex-enoyl]-''N''-methyl-3-(2-naphthyl)alanyl-''N,N''α-dimethyl-<small>D</small>-phenylalaninamide
| image = Tabimorelin skeletal.svg

<!--Clinical data-->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| legal_AU =  
| legal_UK =  
| legal_US =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number =  
| ATC_prefix = none
| ATC_suffix =  
| ATC_supplemental =  
| PubChem = 9810101
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
|  ChemSpiderID = 7985857
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = L51CBE03KF

<!--Chemical data-->
| C=32 | H=40 | N=4 | O=3 
| molecular_weight = 528.683 g/mol
| smiles = CC(C)(C/C=C/C(=O)N(C)[C@H](CC1=CC2=CC=CC=C2C=C1)C(=O)N(C)[C@H](CC3=CC=CC=C3)C(=O)NC)N
|  StdInChI = 1S/C32H40N4O3/c1-32(2,33)19-11-16-29(37)35(4)28(22-24-17-18-25-14-9-10-15-26(25)20-24)31(39)36(5)27(30(38)34-3)21-23-12-7-6-8-13-23/h6-18,20,27-28H,19,21-22,33H2,1-5H3,(H,34,38)/b16-11+/t27-,28-/m1/s1
|  StdInChIKey = WURGZWOTGMLDJP-ZCYANPAGSA-N
| synonyms = <small>((2''E'')-5-amino-5-methylhex-2-enoic acid ''N''-methyl-''N''-((1''R'')-1-(''N''-methyl-''N''-((1''R'')-1-(methylcarbamoyl)-2-phenylethyl)carbamoyl)-2-(2-naphthyl)ethyl)amide)</small>
}}

'''Tabimorelin''' ([[International Nonproprietary Name|INN]]) (developmental code name '''NN-703''') is a [[drug]] which acts as a potent, [[Oral administration|orally-active]] [[agonist]] of the [[growth hormone secretagogue receptor|ghrelin/growth hormone secretagogue receptor]] (GHSR) and [[growth hormone secretagogue]], mimicking the effects of the [[endogenous]] [[peptide]] [[agonist]] [[ghrelin]] as a stimulator of [[growth hormone]] (GH) release. It was one of the first GH secretagogues developed and is largely a modified [[polypeptide]], but it is nevertheless orally-active ''in vivo''.<ref>Hansen BS, Raun K, Nielsen KK, Johansen PB, Hansen TK, Peschke B, Lau J, Andersen PH, Ankersen M. Pharmacological characterisation of a new oral GH secretagogue, NN703. ''European Journal of Endocrinology''. 1999 Aug;141(2):180-9. {{PMID|10427162}}</ref> Tabimorelin produced sustained increases in levels of GH and [[insulin-like growth factor 1]] (IGF-1), along with smaller transient increases in levels of other hormones such as [[adrenocorticotropic hormone]] (ACTH), [[cortisol]], and [[prolactin]].<ref>Zdravkovic M, Søgaard B, Ynddal L, Christiansen T, Agersø H, Thomsen MS, Falch JE, Ilondo MM. The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703, a novel orally active growth hormone secretagogue in healthy male volunteers. ''Growth Hormone and IGF Research''. 2000 Aug;10(4):193-8. {{PMID|11032702}}</ref><ref>Zdravkovic M, Christiansen T, Eliot L, Agersoe H, Thomsen MS, Falch JF, Søgaard B, Ynddal L, Ilondo MM. The pharmacokinetics, pharmacodynamics, safety and tolerability following 7 days daily oral treatment with NN703 in healthy male subjects. ''Growth Hormone and IGF Research''. 2001 Feb;11(1):41-8. {{PMID|11437473}}</ref> However actual clinical effects in adults with [[growth hormone deficiency]] were limited, with only the most severely GH-deficient patients showing significant benefit,<ref>Svensson J, Monson JP, Vetter T, Hansen TK, Savine R, Kann P, Bex M, Reincke M, Hagen C, Beckers A, Ilondo MM, Zdravkovic M, Bengtsson BA, Korbonits M; NN703 Clinical Research Group. Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. ''Clinical Endocrinology''. 2003 May;58(5):572-80. {{PMID|12699438}}</ref> and tabimorelin was also found to act as a [[CYP3A4]] inhibitor which could cause it to have undesirable interactions with other drugs.<ref>Zdravkovic M, Olsen AK, Christiansen T, Schulz R, Taub ME, Thomsen MS, Rasmussen MH, Ilondo MM. A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate. ''European Journal of Clinical Pharmacology''. 2003 Feb;58(10):683-8. {{PMID|12610745}}</ref>

==See also==
* [[Anamorelin]]
* [[Capromorelin]]
* [[Examorelin|Examorelin (hexarelin)]]
* [[GHRP-6|GHRP-6 (SKF-110679)]]
* [[Ibutamoren|Ibutamoren (MK-677)]]
* [[Ipamorelin]]
* [[Macimorelin]]
* [[Pralmorelin|Pralmorelin (GHRP-2)]]
* [[Relamorelin]]
* [[SM-130,686]]

==References==
{{Reflist|2}}


{{GH/IGF-1 axis signaling modulators}}

[[Category:Ghrelin receptor agonists]]
[[Category:Growth hormone secretagogues]]
[[Category:Hormonal agents]]
[[Category:Peptides]]
[[Category:Experimental drugs]]


{{systemic-hormonal-drug-stub}}